Photodynamic therapy with a novel photosensitizer inhibits DSS-induced ulcerative colitis in rats via the NF-κB signaling pathway.

IF 4.8 2区 医学 Q1 PHARMACOLOGY & PHARMACY Frontiers in Pharmacology Pub Date : 2025-01-08 eCollection Date: 2024-01-01 DOI:10.3389/fphar.2024.1539363
Yumei Rong, Minghui Zhu, Nan Wang, Feiyu Zhang, Tianjun Liu
{"title":"Photodynamic therapy with a novel photosensitizer inhibits DSS-induced ulcerative colitis in rats via the NF-κB signaling pathway.","authors":"Yumei Rong, Minghui Zhu, Nan Wang, Feiyu Zhang, Tianjun Liu","doi":"10.3389/fphar.2024.1539363","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Ulcerative colitis (UC) is an inflammatory bowel disease characterized by inflammation and ulceration of the digestive tract.</p><p><strong>Methods: </strong>Photodynamic therapy (PDT) with a novel photosensitizer LD<sub>4</sub> was used to treat UC rat models to explore the therapeutic effect and mechanism of LD<sub>4</sub>-PDT on UC. 16S ribosomal RNA was used to detect the composition of Gut microbiota.</p><p><strong>Results: </strong>Our findings indicate that LD<sub>4</sub>-PDT could protect the integrity of the colonic mucosa, alleviate the inflammatory response and promote the healing of colonic mucosa. Mechanism studies demonstrated that LD<sub>4</sub>-PDT could inhibit the <i>NF-κB</i> signaling pathway, downregulated the expression of the inflammatory factors' tumor necrosis factor-α (TNF-α), interleukin-6 (<i>IL-6</i>) and myeloperoxidase (<i>MPO</i>), increased the contents of glutathione (GSH) and superoxide dismutase (<i>SOD</i>) and decreased the content of malondialdehyde (MDA). Additionally, analysis of gut microbiota revealed that LD<sub>4</sub>-PDT treatment could decrease the abundance of the Proteobacteria phylum in fecal samples, while no significant differences were observed in the Firmicutes, Bacteroidetes, or Actinobacteria phyla among the three groups using 16S rRNA analysis.</p><p><strong>Discussion: </strong>In summary, our data suggested that LD<sub>4</sub>-PDT could inhibit DSS-induced UC in rats via the <i>NF-κB</i> signaling pathway, indicating its potential as a novel photosensitizer for the treatment of UC.</p>","PeriodicalId":12491,"journal":{"name":"Frontiers in Pharmacology","volume":"15 ","pages":"1539363"},"PeriodicalIF":4.8000,"publicationDate":"2025-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11750845/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Pharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3389/fphar.2024.1539363","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Ulcerative colitis (UC) is an inflammatory bowel disease characterized by inflammation and ulceration of the digestive tract.

Methods: Photodynamic therapy (PDT) with a novel photosensitizer LD4 was used to treat UC rat models to explore the therapeutic effect and mechanism of LD4-PDT on UC. 16S ribosomal RNA was used to detect the composition of Gut microbiota.

Results: Our findings indicate that LD4-PDT could protect the integrity of the colonic mucosa, alleviate the inflammatory response and promote the healing of colonic mucosa. Mechanism studies demonstrated that LD4-PDT could inhibit the NF-κB signaling pathway, downregulated the expression of the inflammatory factors' tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6) and myeloperoxidase (MPO), increased the contents of glutathione (GSH) and superoxide dismutase (SOD) and decreased the content of malondialdehyde (MDA). Additionally, analysis of gut microbiota revealed that LD4-PDT treatment could decrease the abundance of the Proteobacteria phylum in fecal samples, while no significant differences were observed in the Firmicutes, Bacteroidetes, or Actinobacteria phyla among the three groups using 16S rRNA analysis.

Discussion: In summary, our data suggested that LD4-PDT could inhibit DSS-induced UC in rats via the NF-κB signaling pathway, indicating its potential as a novel photosensitizer for the treatment of UC.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
新型光敏剂光动力疗法通过NF-κB信号通路抑制dss诱导的大鼠溃疡性结肠炎。
简介:溃疡性结肠炎(UC)是一种以消化道炎症和溃疡为特征的炎症性肠病。方法:采用新型光敏剂LD4光动力疗法(PDT)治疗UC大鼠模型,探讨LD4-PDT对UC的治疗作用及机制。采用16S核糖体RNA检测肠道菌群组成。结果:LD4-PDT具有保护结肠黏膜完整性、减轻炎症反应、促进结肠黏膜愈合的作用。机制研究表明,LD4-PDT可抑制NF-κB信号通路,下调炎性因子肿瘤坏死因子-α (TNF-α)、白细胞介素-6 (IL-6)和髓过氧化物酶(MPO)的表达,提高谷胱甘肽(GSH)和超氧化物歧化酶(SOD)含量,降低丙二醛(MDA)含量。此外,肠道菌群分析显示,LD4-PDT处理可以降低粪便样品中变形菌门的丰度,而在16S rRNA分析中,三组之间厚壁菌门、拟杆菌门或放线菌门的丰度没有显著差异。综上所述,我们的数据表明LD4-PDT可以通过NF-κB信号通路抑制dss诱导的大鼠UC,表明其作为一种新型光敏剂治疗UC的潜力。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Frontiers in Pharmacology
Frontiers in Pharmacology PHARMACOLOGY & PHARMACY-
CiteScore
7.80
自引率
8.90%
发文量
5163
审稿时长
14 weeks
期刊介绍: Frontiers in Pharmacology is a leading journal in its field, publishing rigorously peer-reviewed research across disciplines, including basic and clinical pharmacology, medicinal chemistry, pharmacy and toxicology. Field Chief Editor Heike Wulff at UC Davis is supported by an outstanding Editorial Board of international researchers. This multidisciplinary open-access journal is at the forefront of disseminating and communicating scientific knowledge and impactful discoveries to researchers, academics, clinicians and the public worldwide.
期刊最新文献
Discovery of potent bisindole-based pyrazolopyridine derivatives as topoisomerase inhibitors: DNA damage induction and synergistic antileukemic activity. The role of immune regulation in peripheral nerve regeneration: functions of inflammatory cells and cytokines. Anticoagulant-free preparation of autologous platelet-rich plasma (PRP) / fluid platelet-rich fibrin (f-PRF): a pre-clinical comparative performance study. Epidemiological relevant effect biomarkers for thyroid hormone system related adverse outcome pathways: a literature review. AI-driven pilot platforms and computational pharmaceutics: accelerating innovation in small molecule drug development under industry 4.0 and 5.0 paradigms.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1